Edition:
United States

Profile: Vernalis PLC (VER.L)

VER.L on London Stock Exchange

12.50GBp
17 Oct 2017
Change (% chg)

0.12 (+1.01%)
Prev Close
12.38
Open
12.75
Day's High
12.75
Day's Low
12.00
Volume
815,765
Avg. Vol
211,040
52-wk High
40.00
52-wk Low
10.00

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.

Company Address

Vernalis PLC

100 Berkshire Place, Wharfedale
WOKINGHAM     RG41 5RD
P: +44118.9380000
F: +44118.9380001

Company Web Links